Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.

Cell death & disease - 8 Sept 2016

Klingbeil Olaf, Lesche Ralf, Gelato Kathy A, Haendler Bernard, Lejeune Pascale

Abstract excerpt

Non-small cell lung cancer (NSCLC) has the highest incidence of cancer-related death worldwide and a high medical need for more effective therapies. Small-molecule inhibitors of the bromodomain and extra terminal domain (BET) family such as JQ1, I-BET762 and OTX-015 are active in a wide range of different cancer types, including lung cancer. Although their activity on oncogene expression such as c-Myc has been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Azepines
Share to Benzodiazepines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterocyclic Compounds, 3-Ring

Share to Proto-Oncogene Proteins c-myc

Share to TNF-Related Apoptosis-Inducing Ligand

Share to Triazoles

Share to X-Linked Inhibitor of Apoptosis Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 27607580
DOI: 10.1038/cddis.2016.271
PMCID: PMC5059870

Genes

KRAS
XIAP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.PMID 27607580Read ↗

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 InhibitorsSemantic proximity Read ↗

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteinsSemantic proximity Read ↗

BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family MembersSemantic proximity Read ↗

Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung CancerSemantic proximity Read ↗

Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic ResponseSemantic proximity Read ↗

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer CellsSemantic proximity Read ↗

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.Semantic proximity Read ↗

Apoptosis and lung cancer: a review.Semantic proximity Read ↗

Targeting BET bromodomain proteins in cancer: The example of lymphomasSemantic proximity Read ↗

In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker GenesSemantic proximity Read ↗

<i>In Silico</i> Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.